GlassScriptPhysician profile
Kenneth Spiller
NPI 1043220239
$1,335.31
in general payments reported to CMS, 2019-2025
23 companies · $209 in 2025
The $209 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $536 · 2020: $42.52 · 2021: $50.90 · 2022: $131 · 2023: $74.25 · 2024: $292 · 2025: $209.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $575.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $575.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $232.69 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $138.54 | 2019-2020 | |
| Abbvie INC. | $132.49 | 2021-2024 | Vraylar |
| Astellas Pharma US INC | $126.57 | 2019-2024 | Veozah |
| Novo Nordisk INC | $86.22 | 2019-2025 | Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $63.56 | 2024-2025 | Farxiga, Airsupra |
| Dexcom, INC. | $60.87 | 2024-2025 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $49.01 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $48.36 | 2022-2025 | |
| Amgen INC. | $44.21 | 2019 | |
| Glaxosmithkline, LLC. | $43.28 | 2019 | |
| Allergan, INC. | $39.77 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $39.30 | 2019 | |
| Ironwood Pharmaceuticals, INC | $35.43 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $27.27 | 2024-2025 | Voquezna |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $25.72 | 2019 | |
| Sanofi Pasteur INC. | $25.23 | 2019 | |
| Axsome Therapeutics, INC. | $23.58 | 2023 | Sunosi |
| Teva Pharmaceuticals USA, INC. | $23.18 | 2019 | |
| Ardelyx, INC. | $18.57 | 2025 | Ibsrela |
| Novartis Pharmaceuticals Corporation | $18.41 | 2024 | |
| Boston Scientific Corporation | $17.54 | 2022 | |
| Abbott Laboratories | $15.51 | 2023 | Freestyle Libre 3 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Spiller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.